TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable, pulmonary arterial hypertension diagnosed as either idiopathic or familial PAH, collagen vascular disease associated PAH, HIV PAH, or PAH induced by anorexigens, New York Heart Association (NYHA) Class III or Class IV.~* Been on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of sildenafil for at least three months prior to study start~* An unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening~* Cardiac catheterization within the past 13 months consistent with PAH, specifically mean pulmonary artery pressure (PAPm) ≥25 mmHg (at rest), pulmonary capillary wedge pressure (PCWP) (or left ventricular end diastolic pressure) ≤15 mmHg, and pulmonary vascular resistance (PVR) \>3 mmHg/L/min~* Within the past 12 months, patients must have had a chest radiograph consistent with the diagnosis of PAH~* Willing and able to follow all study procedures~Exclusion Criteria:~* Considering pregnancy, are pregnant and/or lactating~* PAH due to conditions other than noted in the above inclusion criteria.~* Have had any change in or discontinued any PAH medication within the last three months, including but not limited to endothelin receptor antagonist (ERA), or calcium channel blockers (CCB) (with the exception of anticoagulants)~* Have received any prostanoid within the 30 days before screening or are scheduled to receive any during the course of the study~* Have received any investigational medication within 30 days prior to the start of this study or are scheduled to receive another investigational drug during the course of this study~* Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids~* Have an increased risk of hemorrhage~* Have a new type of chronic therapy (e.g., a different category of vasodilator, diuretic) for PAH added within the last month, except anticoagulants~* Have any musculoskeletal disease or any other disease that would limit ambulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled treprostinil (Type: EXPERIMENTAL): 0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
- Placebo (Type: PLACEBO_COMPARATOR): Placebo inhalation solution for use in ultrasonic nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic breast cancer~* Eastern Cooperative Oncology Group (ECOG) 0 or 1~* HER2-expressing primary or metastatic tumor~* Recurrence within 1 year completing adjuvant trastuzumab OR rapid progress following first-line trastuzumab-based care.~* Measurable disease with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1~* Normal organ function, including bone marrow function, renal function, liver function, and cardiac function~* Signed and dated an informed consent form~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breast feeding~* left ventricular ejection fraction (LVEF) \< 45% by echocardiogram~* Disease-free interval (DFI) less than 12 months~* Uncontrolled medical problems~* Any previous malignancy exceptions for carcinoma of the cervix, squamous carcinoma of the skin, or basal cell carcinoma of the skin~* Patients were unable or unwilling to comply with program requirements

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lapatinib and Capecitabine or Vinorelbine (Type: EXPERIMENTAL): Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Danazol for Genetic Bone Marrow and Lung Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Short age-adjusted telomere length in the first percentile and/or a mutation in telomerase genes~ 2. One or more of the following cytopenia(s).~* Anemia~  1. Symptomatic anemia with a hemoglobin \< 9.5 g/dL or red cell transfusion requirements \> 2 units/month for at least 2 months~ 2. Reticulocyte count \< 60,000 /microL~* Thrombocytopenia~  1. Platelet count \< 30,000 /microL or \< 50,000 /microL associated with bleeding~ 2. Decreased megakaryocytic precursors in the bone marrow~* Neutropenia~  1. Absolute neutrophil count \< 1,000 /microL~     OR~     3. Idiopathic pulmonary fibrosis diagnosed by either a lung biopsy of high resolution computed tomography scan of the chest according to guidelines from the American Thoracic Society and European Respiratory Society~     4. Age greater than or equal to 2 years~     5. Weight \> 12 kg~     EXCLUSION CRITERIA:~    1. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient s ability to tolerate protocol therapy, or that death within 30 days is likely~    2. Potential subjects with cancer who are on active chemotherapeutic treatment~    3. Current pregnancy, or unwillingness to avoid pregnancy if of childbearing potential~    4. Not able to understand the investigational nature of the study or give informed consent or does not have a legally authorized representative or surrogate that can provide informed consent.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danazol (Type: EXPERIMENTAL): Single arm in which danazol is administered orally at 800 mg daily for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18-60 years~* BMI \> 20kg/m2 and \<35kg/m2~Exclusion Criteria:~* Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study~* Use of GH or growth hormone stimulating peptides within six months of starting the study~* Change in lipid lowering or antihypertensive regimen within 3 months of screening~* Fasting blood sugar \> 126 mg/dL, SGOT \> 2.5 times ULN, Hgb \< 12.0 g/dL, creatinine \> 1.4 mg/dL~* Carpal tunnel syndrome~* Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~* For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5 ng/mL~* Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis~* Weight \< 110 lbs.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Growth Hormone Releasing Hormone (Type: EXPERIMENTAL): Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Intensity Interval Training Versus Circuit Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants reported no medical history of cardiometabolic or limiting respiratory disease, were non-smokers, had a body mass index \<30 kg.m-2, classified as recreationally active~Exclusion Criteria:~* Cardiometabolic disease, high activity levels, Unable to tolerate the exercise intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- High intensity interval training (Type: EXPERIMENTAL): HIIT was set at \> 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
- Circuit training (Type: ACTIVE_COMPARATOR): The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microcurrent Dressing to Treat Infections, Before, During and After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Limited to total or reverse shoulder arthroplasty~* All patients 18 years of age and older~Exclusion Criteria:~* Under the age of 18~* Revision shoulder arthroplasty patients~* Sensitivity or allergy to sliver or zinc or latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
- Group B (Type: EXPERIMENTAL): This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 and ≤65 years old;~2. Subjects who are receiving statin therapy at the time of screening or who are eligible for statin therapy can randomized to receive a stable dose of statin therapy for more than 28 days and are willing to maintain stable statin therapy in this study;~3. Low-density lipoprotein cholesterol (LDL-C) level ≥2.6mmol/L of subjects who receiving statin and/or other lipid-lowering therapy at the time of screening, or LDL-C≥ 3.4mmol/L of subjects who didn't receive any-lowering therapy at the time of screening, and LDL-C still ≥2.6mmol/L before randomization;~4. Fasting triglycerides ≤4.5 mmol/L;~5. Body mass index (BMI) ≥18 and ≤ 35 kg/m2;~6. Signed informed consent.~Exclusion Criteria:~1. A clinical history of drug allergy or a history of atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known allergy to experimental or similar experimental drugs;~2. Diagnosis of homozygous familial hypercholesterolemia;~3. New York heart association (NYHA) defined Ⅱ - Ⅳ history of heart failure;~4. History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina), or percutaneous coronary intervention, or coronary artery bypass graft, or history of cerebrovascular disease, within 12 months prior to screening;~5. Uncontrolled severe arrhythmias that are not controlled by drugs or other therapy within 12 months prior to enrollment;~6. Uncontrolled hypertension (systolic blood pressure ≥ 160 and/or diastolic blood pressure ≥ 100 mmHg);~7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or gamma pancreatic acyl transferase (GGT), more than 2.5x ULN;~8. Subjects with previous malignant tumor diseases. etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1209 (Type: EXPERIMENTAL): Participants received one of 6 dose levels of SHR-1209 administered as multiple subcutaneous doses.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo dose regimens by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* GAD diagnosis by structured interview~* Hamilton Anxiety Scale score of 18 or MORE~* Clinical Global Impressions Severity Scale score of at least 4~* Hamilton Depression Scale score of 18 or less~* Hamilton Depression Scale suicide item score less than 2~* Use of an effective form of contraception throughout the study~Exclusion Criteria:~* Hypersensitivity to venlafaxine XR~* History of seizures~* Episode of major depressive disorder in the previous 6 months~* History of any psychotic illness, bipolar disorder, or dementia~* Substance abuse and dependence during the past 6 months~* Other anxiety disorders with the exception of social phobia as long as GAD is primary~* Regular use of anxiolytics or antidepressants within 7 days of study onset~* Use of fluoxetine or monoamine oxidase inhibitors within 28 days of study onset (low dose usage of benzodiazepines will not prevent participation)~* Use of other psychotropic medication besides benzodiazepines during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label Group (Type: ACTIVE_COMPARATOR): 6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
- Double-Blind Drug Group (Type: ACTIVE_COMPARATOR): 6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
- Double-Blind Placebo Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
- Double-Blind Drug-After-Drug Group (Type: ACTIVE_COMPARATOR): 6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
- Double-Blind Placebo-After-Drug Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
- Double-Blind Placebo-After-Placebo Group (Type: PLACEBO_COMPARATOR): 6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibrin Glue in Inguinal Lymphadenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Patients scheduled to perform ILND for various causes~Exclusion Criteria:~* BMI more than 35,~* Uncompensated diabetes~* Advanced liver disease~* Previous history of surgery and/or irradiation to the inguinal region~* Preoperative chemotherapy~* Significant coagulation disorders~* Platelet counts \<100,000/mL.~* Use of systemic steroids or anticoagulants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibrin glue (Type: EXPERIMENTAL): A fibrin glue was applied to the lymphadenectomy bed before wound closure and insertion of a drain.
- Control (Type: NO_INTERVENTION): Lymphadenctomy wound was closed after insertion of a drain,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients being evaluated for Alzheimer disease and related dementias according to the HAS recommendations (atypical dementia, early onset and rapid progressive dementia)~* Patients who have previously been evaluated for AD and related dementias to whom a CSF examination was recommended in the last 12 months, but lumbar puncture was contraindicated or refused or CSF results were ambiguous, or~* Patients currently being evaluated for AD and related dementias to whom a CSF examination is recommended but lumbar puncture is contraindicated or refused~* Patients have a study partner who is willing and able to accompany him/her to all clinic visits for the duration of the protocol~* Patients able to complete all clinical visits according to the protocol~* Patients able to tolerate a 20-minute FBB PET scan~* Patient or legal representative to provide informed consent for study participation, visits and data source verification.~Exclusion Criteria:~* The subject had a previous beta amyloid imaging scan~* Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol~* Is currently receiving any investigational pharmaceutical product or has participated in a clinical trial with an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study~* For females of childbearing age, a positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Neuraceq (florbetaben 18F) PET scan (Type: EXPERIMENTAL): A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Diagnosed with breast cancer~* Indicated for the adjuvant treatment for breast cancer~* Between 18 years and 75 years~* Alphabetized~Exclusion Criteria:~* Undergone chemotherapy or radiotherapy before inclusion in the study.~* Pregnant~* Epilepsy~* Brain Stroke~* Multiple sclerosis~* BMI above 45 kg / m 2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): Melatonin 20 mg Oral Capsules, once a day at bedtime
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Oral Capsules, once a day at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mantle cell lymphoma (MCL) confirmed with histology, immunophenotype, and cyclin D1 analysis~* Received 2 to 7 prior therapies which may include hematopoietic stem cell transplant (i.e. induction + consolidation + maintenance)~* Prior treatment with an alkylating agent and an anthracycline, rituximab, individually or in combination, and status that is at least one of the following:~* Primary disease refractory to at least 2 regimens;~* Refractory to at least 1 regimen after first relapse;~* Refractory or untreated after second or greater relapse;~* Refractory to first line and relapsed after second line. Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).~Exclusion Criteria:~* Subjects who are less than or equal to six month from allogeneic hematopoietic stem cell transplant and who are on immunosuppressive therapy or have evidence of graft versus host disease~* Prior investigational therapy within 3 weeks of first dose. Investigational therapy is defined as treatment that is not approved for any indication.~* Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth. (Treated CNS metastases must be stable for \> 2 weeks prior to Day 1.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete